Yohann Loriot
MD, PhD
Medical Oncologist
👥Biography 个人简介
Yohann Loriot is a leading European bladder cancer oncologist whose work on FGFR alterations in urothelial carcinoma was instrumental in the clinical development of erdafitinib. He led the BLC2001 trial that resulted in FDA approval of erdafitinib for FGFR-altered urothelial cancer. His research has advanced understanding of the genomic landscape of bladder cancer and the identification of targetable alterations. He is a principal investigator in multiple European and global bladder cancer trials.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Yohann Loriot 的研究动态
Follow Yohann Loriot's research updates
留下邮箱，当我们发布与 Yohann Loriot（Institut Gustave Roussy）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment